Market Size
The global limb-girdle muscular dystrophy market is estimated to be valued at US$ 1.50 billion in 2025 and is expected to reach US$ 2.65 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2026-2033.
Limb-girdle muscular dystrophy (LGMD) is a group of diseases that cause proximal muscle weakness and wasting in the limbs. The condition is caused by the inheritance of a disease-causing mutated gene whose original role is to encode the essential components required for muscle growth and maintaining muscle strength. There are two major groups of LGMDs called LGMD1 and LGMD2, which are classified based on respective inheritance patterns and genetic causes. If one copy of the abnormal gene is sufficient to cause the disease, it is said to be autosomal dominant and if two copies are needed, then the inheritance pattern is autosomal recessive.
The disease can affect the person at any life stage like childhood, adolescence, adulthood, and geriatric. If the condition affects the childhood phase, the progression can be rapid and the level of disability is higher.
There is no cure for limb-girdle muscular dystrophy at present, the current treatment options include physical therapy, corticosteroids, which provide symptomatic relief, and mobility aids which can help with movement. Currently, disease-modifying therapies such as gen therapies are being explored as a novel treatment option for this condition.
Market Scope
| Metrics | Details |
| CAGR | 7.4% |
| Market Size | 2023-2033 |
| Market Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Type, Treatment Type, and End-Users |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Rising development of advanced therapies for limb-girdle muscular dystrophy
Currently, there is no specific treatment available for limb-girdle muscular dystrophy. Existing therapies such as physical therapy, respiratory and heart care, behavioral therapy, and some medication for symptomatic relief. All these treatments aim at alleviating symptoms and providing temporary relief to the patient. It is high time to bring novel therapies into the market that can modify the disease and help in the reversal of the condition. Several companies have been investing in and developing these novel therapies, which are currently in investigational trials and are anticipated to be launched into the market. These novel therapies, once launched, can revolutionize the limb-girdle muscular dystrophy market.
Moreover, ML Bio Solutions, Inc. has developed a novel drug called BBP-418 (Ribitol) which is currently being investigated in phase 3 of clinical trials. The study aims to evaluate the safety and efficacy of long-term administration of BBP-418 in limb-girdle muscular dystrophy patients. The study is anticipated to be finished by mid-2027.
Restraints
The high cost of treatment can be a restraining factor for the market growth in the forecast period. The patient with limb-girdle muscular dystrophy may need long-term treatment, which can be expensive for some patient populations. This can be troublesome to patients living in low and middle-income countries.
Market Segment Analysis
The global limb-girdle muscular dystrophy market is segmented based on type, treatment type, end-users, and region.
Physical therapy in the treatment type segment accounted for approximately 34.2% of the global limb-girdle muscular dystrophy market share
There is no specific treatment for limb-girdle muscular dystrophy. The condition is characterized by progressive proximal muscle loss in the limbs especially in the legs. This can cause symptoms such as pain, weakness, inability to walk and climb, and inability to lift heavy objects, eventually leading to the necessity of walking aids. The currently available treatment for this condition is only supportive in terms of physical therapy, occupational therapy, medication like corticosteroids to manage inflammation and respiratory and cardiac care.
Physical therapy plays a crucial role in managing the symptoms of this condition. Regular physical exercise can help to maintain mobility and delay muscle loss. The primary goal of physical therapy is to improve movement in the joints and to prevent their tightening. These problems can arise when movement is limited, so patients need to continue to move as much as they can. Activities such as aerobic exercise, submaximal strength training, upper limb exercises, and coordination activities can help the patient to be active and retain their mobility.
Market Geographical Share
North America is expected to dominate the market with a share of 41.3% in the global limb-girdle muscular dystrophy market
The region has well-established healthcare facilities that can provide tailored treatment options to patients. North America’s advanced healthcare system enables patients to undergo screening at an early stage so that a tailored treatment can be planned according to their needs. The countries in the region such as the U.S. and Canada have highly advanced rehabilitation centers with ease of access to patients suffering from this condition.
In addition, the U.S. has organizations that strive to provide healthcare access to patients, support advanced research activities, and support care centers. For instance, The Muscular Dystrophy Association (MDA) is one such organization located in the U.S. in more than 150 of the top healthcare institutions. MDA’s Care Center Network offers tens of thousands of appointments each year for individuals living with muscular dystrophy, ALS, and other neuromuscular diseases to access expert multidisciplinary care, and clinical trials, and to connect with MDA and the neuromuscular community.
Moreover, several medical institutes, research centers, and pharmaceutical and biopharmaceutical companies are creating innovations in the treatment of limb-girdle muscular dystrophy. For instance, the California Institute of Regenerative Medicine had received a grant for developing novel stem cell therapy which is aimed to promote healthy muscle growth in limb-girdle muscular dystrophy 2b patients. All these factors contribute to the region’s dominance in the forecast period.
Market Segmentation
By Type
- Limb-Girdle Muscular Dystrophy Type 1
- Limb-Girdle Muscular Dystrophy Type 2
By Treatment Type
- Physical Therapy
- Medication
- Occupational Therapy
- Respiratory and Cardiac Care
- Mobility Aids
- Others
By End-Users
- Hospitals & Clinics
- Homecare
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Competitive Landscape
The major players in the limb-girdle muscular dystrophy market include Horizon Therapeutics plc, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Viatris Inc., Atamyo Therapeutics, Sarepta Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., ML Bio Solutions, Inc., Genethon and Edgewise Therapeutics among others.
Key Industry Developments
March 2026: Atamyo Therapeutics completed dosing of the first three patients with its investigational AAV‑based gene therapy ATA‑200 in a phase 1b/2 trial for LGMD‑R5 (LGMD2C), marking a key clinical milestone in gene‑replacement therapy for this severe limb‑girdle subtype and advancing the read‑out of early‑stage safety and biomarker data.
March 2025: AskBio (a Bayer‑owned gene‑therapy subsidiary) advanced its LION‑CS101 phase 1/2 clinical trial for AB‑1003, an investigational gene therapy for LGMD2I/R9, by initiating the first participant in the second dose‑escalation cohort following a positive data‑safety review, reinforcing the platform’s progression toward higher‑dose cohorts and broader patient recruitment.
June 2025: Sarepta Therapeutics received FDA platform‑technology designation for its investigational rAAVrh74‑based gene‑therapy vector bidridistrogene xeboparvovec (SRP‑9003) for LGMD2E, accelerating the regulatory pathway for this vector backbone and enabling more efficient development of future LGMD‑targeted gene‑therapy candidates under the same platform.
Why Purchase the Report?
- To visualize the global limb-girdle muscular dystrophy market segmentation based on type, treatment type, end-users, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of limb-girdle muscular dystrophy market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global limb-girdle muscular dystrophy market report would provide approximately 62 tables, 54 figures, and 187 Pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
